Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
專家展望：5位分析師眼中的Mersana Therapeutics
Ratings for Mersana Therapeutics (NASDAQ:MRSN) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中，有5位分析師提供了Mersana Therapeutics（納斯達克股票代碼：MRSN）的評級，顯示了看漲和看跌的觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Mersana Therapeutics, presenting an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. This upward trend is apparent, with the current average reflecting a 103.08% increase from the previous average price target of $3.25.
在評估12個月目標股價時，分析師公佈了對Mersana Therapeutics的見解，將平均目標股價定爲6.6美元，最高估計爲9.00美元，低估值爲5.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的平均目標價3.25美元上漲了103.08％。
Breaking Down Analyst Ratings: A Detailed Examination...
分解分析師評級...
登入免費觀看全文
登入/註冊